Alentis Therapeutics AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alentis.ch
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Conditions
- Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 170
- Registration Number
- NCT06747585
- Locations
- ๐บ๐ธ
Providence Medical Foundation, Fullerton, California, United States
๐บ๐ธUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธYale Comprehensive Cancer Center, New Haven, Connecticut, United States
Study of ALE.C04 in Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT06054477
- Locations
- ๐บ๐ธ
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธUniversity of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธYale University Yale Cancer Center, New Haven, Connecticut, United States
Rescue of Nephrons With ALE.F02 (RENAL-F02)
- Conditions
- Glomerulonephritis Rapidly Progressive
- Interventions
- Drug: PlaceboDrug: Immunosuppressive Agents
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 80
- Registration Number
- NCT06047171
- Locations
- ๐จ๐ฟ
Vseobecna fakultni nemocnice v Praze, Prague, Czechia
๐จ๐ฟInstitut klinicke a experimentalni mediciny, Praha 4, Czechia
๐ฉ๐ฐAalborg University Hospital, Aalborg, Denmark
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/or with Mild Cirrhosis
- Conditions
- Advanced liver fibrosis and/or mild liver cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 37
- Registration Number
- 2024-516455-40-00
- Locations
- ๐ท๐ด
Arensia Exploratory Medicine S.R.L., Bucharest, Romania
๐ท๐ดSpitalul Clinic Judetean De Urgenta Cluj, Cluj-Napoca, Romania
๐ธ๐ฐSummit Clinical Research s.r.o., Malacky, Slovakia